Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Here, we describe the effect of an orally available medication, danegaptide, in regulating retinal vascular permeability in preclinical animal models of disease and report safety and early efficacy data from an early-stage phase 1b clinical trial in patients with NPDR and mild center-involved macular edema.
Limitation the authors admit
These findings support larger clinical trials to test efficacy.
Appeared: Friday, September 25. Science Translational Medicine. Peer-reviewed journal.